SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (345)11/20/2000 1:14:32 PM
From: Edwin S. Fujinaka  Respond to of 668
 
I saw the Forbes Article on the Roach Motel syndrome <G>. I think the estimate of the cash on hand did not include the money that they recently aquired at $9/share. I suppose selling stock at $9 is a lot like some of us answering margin calls by selling Curis stock at these prices. If OP-1 is approved in Europe or anywhere else and Sykes begins to deliver product, CRIS should really begin to take off. It seems like that ought to be soon. (Earlier predictions from the Company were for the end of this year.)



To: Jim Oravetz who wrote (345)11/20/2000 2:43:56 PM
From: tom r. phillips  Respond to of 668
 
"Says Platika, "Look for additional M&A deals." "

the $50 million in cash referred to in the Forbes article was pre-private placement. adds up.

Tom


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News